Candel Therapeutics (CADL) Asset Utilization Ratio (2021 - 2022)
Candel Therapeutics (CADL) reported Asset Utilization Ratio of 0.0 for Q4 2022, up 42.55% on a YoY basis from 0.0 in Q4 2021, and up 37.27% sequentially from 0.0 in Q3 2022.
Candel Therapeutics (CADL) Asset Utilization Ratio (2021 - 2022) Analysis & Trends
Candel Therapeutics (CADL) has 2 years of Asset Utilization Ratio data on file, last reported at 0.0 in Q4 2022.
- For the quarter ending Q4 2022, Asset Utilization Ratio rose 42.55% year-over-year to 0.0; the trailing twelve-month figure through Dec 2022 stood at 0.0 (up 42.55% YoY), and the FY2022 full-year result was 0.0, down 4.52% from the prior year.
- Asset Utilization Ratio rose to 0.0 in Q4 2022, from 0.0 in the prior quarter.
- In the past five years, Asset Utilization Ratio ranged from a high of 0.0 in Q3 2021 to a low of 0.0 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 0.69 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 0.47 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 0.37 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Candel Therapeutics | 542.51 Mn | 542.51 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 0.00 |
| Sep 30, 2022 | 0.00 |
| Jun 30, 2022 | 0.00 |
| Mar 31, 2022 | 0.00 |
| Dec 31, 2021 | 0.00 |
| Sep 30, 2021 | 0.00 |